⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALLO News
Allogene Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
ALLO
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
globenewswire.com
ALLO
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026
globenewswire.com
ALLO
Cell Therapy Market Size to Surpass USD 17.15 Billion by 2032, Driven by Chronic Disease Treatment and CAR-T Therapy Growth, Says New MMR Analysis
prnewswire.com
GILD
JNJ
BMY
REGN
VERI
RXRX
MAGN
ALLO
Form 8-K
sec.gov
ALLO
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
globenewswire.com
ALLO
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
globenewswire.com
ALLO
CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™
prnewswire.com
BMY
GILD
JNJ
CRSP
ALLO
CART
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
globenewswire.com
ALLO
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
globenewswire.com
ONCY
ALLO
CHRS
PYXS
ELVN